SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (27)4/27/1996 6:35:00 PM
From: Lyle Abramowitz   of 305
 
Trial results for ALLERVAX Cat released 4/26

Apparently, the market did not like the results which did not exhibit statistically significant improvement in symptons in certain test groups. In some instances efficacy of the treatment was indicated. Company said they are satisfied with the results, pointing out that the weaker response was with low doses and better results ocurred with higher doses. Similar results were reported about a year ago and the stock reacted negatively also. The news story and the company's press release can be found on the On-line WSJ briefing book for IMUL. I do not know enough about the test results or how they are properly interpreted to provide an opinion as to whether the market's response is appropriate.

Lyle
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News